Results

1–10 of 31 results for anti-VEGF therapy

Baseline Characteristics Associated With Catastrophic Vision Loss Due to Subretinal Hemorrhage in Patients Undergoing Treatment for Neovascular Macular Degeneration
Eric W Schneider, MD
Annual Meeting Talks
2024
Subretinal Delivery of Investigational ABBV-RGX-314 for Neovascular Age-Related Macular Degeneration: A Phase II Pharmacodynamic Study
Edward H. Wood, MD, FASRS
Annual Meeting Talks
2024
Impact of COVID-19 and Delay on Macular Edema After Retinal Vein Occlusion (MEfRVO) Comparing Ozurdex vs Anti-VEGF Therapy
John J. Huang, MD
Annual Meeting Talks
2022
Anti-VEGF Therapy to Prevent Macular Fibrosis in Coats Disease
On Demand Cases, Courses, and Papers
2022
Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model
Andrew A. Moshfeghi, MD, MBA, FASRS
On Demand Cases, Courses, and Papers
2021
Clinical Features and Outcomes of Infants With Retinopathy of Prematurity Who Fail Anti-VEGF Therapy (FELLOWS FORUM AWARD WINNER)
Lucy T Xu, MD
Annual Meeting Talks
2021
Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States
Rahul N. Khurana, MD, FASRS
Annual Meeting Talks
2021
Clinical Trial Versus Real-World Outcomes With Anti-VEGF Therapy for Branch and Central Retinal Vein Occlusion
Carl J Danzig, MD
Annual Meeting Talks
2021
Intravitreal Anti-VEGF Therapy in Maintaining Long-term Driving Vision in Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration
Parisa Emami Naeini, MD, MPH, FASRS
Annual Meeting Talks
2021
Efficacy and Durability of Brolucizumab in Patients Being Transitioned From Prior Anti-VEGF Therapy
Scott D Walter, MD, MSc, FASRS
Annual Meeting Talks
2021